Biomarkers Consortium Releases Data from Alzheimer's Disease Study

The study is intended to be the first part of multi-phase work to use samples collected by ADNI to qualify multiplex panels in both plasma and cerebrospinal fluid for diagnosing patients with Alzheimer's and monitoring their disease progression.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.